CPESN USA, a clinically integrated, nationwide organization of pharmacy networks created to advance community-based pharmacy practice, announced the winner of the 2024 CPESN Luminary-of-the-Year Award, sponsored by Prasco. CPESN Missouri luminary Chri
CPESN USA Wins SAS Community Uplift Award
08 May 2024CPESN USA was recognized with the 2024 SAS Customer Recognition Award in the Community Uplift Category, awarded to a SAS customer who has made an impact in their community at large using SAS products.
Click here to learn more.
CPESN Arkansas Announces Morris as Executive Director
15 Mar 2024CPESN Arkansas recently announced Bri Morris, PharmD, as its new executive director. Dr. Morris is the first executive director in the organization’s history. The announcement was covered in Arkansas Money & Politics. Click here for the story.
CPESN LTC@Home Featured in America's Pharmacist
03 Mar 2024CPESN LTC@Home – the newest CPESN Special Purpose Network – and their Facilitator Lindsay Dymowski Constantino were featured in the March edition of America's Pharmacist.
Click here to read the complete article.
CPESN Max My Sync Team Featured
08 Feb 2024CPESN Beacons Chelsea Anderson, Tiffany Capps, and Weston Humphreys -- co-hosts of the Flip the Pharmacy Max My Sync series -- are featured in the February 2024 issue of America's Pharmacist in an article entitled, "Getting in Sync." Click here for the article.
CPESN Health Equity Luminary Logan Highlighted in I AM NCPA
06 Feb 2024CPESN USA and CPESN Health Equity luminary Tripp Logan, owner of SEMO Pharmacies in Southeastern Missouri, was highlighted in the I AM NCPA feature in the February edition of America's Pharmacist. Logan shares his passion for CPESN Health Equity. Click here for the feature.
NCPA CEO Hoey Leads with CPESN Networks
10 Jan 2024National Community Pharmacist Association CEO Doug Hoey calls out CPESN Networks and says having pharmacists reimbursed for the primary care services they provide is a key pillar to changing the pharmacy payment model in his Health Care Outlook for 2024. Click here for the article as it appeared in Chain Drug Review.